Last reviewed · How we verify
Placebo of CDP870
Placebo of CDP870 is a Small molecule drug developed by Otsuka Pharmaceutical Co., Ltd.. It is currently in Phase 3 development.
This is a placebo control arm and contains no active pharmaceutical ingredient.
At a glance
| Generic name | Placebo of CDP870 |
|---|---|
| Sponsor | Otsuka Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a placebo, this formulation is inert and produces no pharmacological effect. It is used in clinical trials as a control comparator to assess the efficacy and safety of the active drug CDP-870 (certolizumab pegol, a TNF-alpha inhibitor) against baseline and non-specific effects.
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis (PHASE3)
- A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis (PHASE2)
- SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
- Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis (PHASE3)
- Certolizumab in Recurrent Implantation Failure (RIF) (PHASE3)
- A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis (PHASE2)
- Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS (PHASE3)
- A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo of CDP870 CI brief — competitive landscape report
- Placebo of CDP870 updates RSS · CI watch RSS
- Otsuka Pharmaceutical Co., Ltd. portfolio CI
Frequently asked questions about Placebo of CDP870
What is Placebo of CDP870?
How does Placebo of CDP870 work?
Who makes Placebo of CDP870?
What development phase is Placebo of CDP870 in?
Related
- Manufacturer: Otsuka Pharmaceutical Co., Ltd. — full pipeline
- Compare: Placebo of CDP870 vs similar drugs
- Pricing: Placebo of CDP870 cost, discount & access